Raygent Biopharmaceutical Portfolio: Celgene (CELG) and Gilead (GILD) Ignite Rally
A languishing biotech sector rallied today with clinical news with Hepatitis C (HCV) drugs. The Rayno Biopharma Portfolio was up 2.4% led by Gilead Sciences (GILD) up 11.5%, Regeneron (REGN) up 3.3% and ViroPharma (VPHM) up 3.2%. Gilead shares were up $7.50 on favorable Phase 2 results with...
Rayno Life Science: Biotechnology Sector Should Find Support Today
Trends from early trading show promise for intermediate support in larger cap biotech shares today with the NASDAQ up 0.5% in early trading. This could be a good day for covering shorts and re-balancing in anticipation for a Q4 rally : The IBB (130.82) is up 1.88%. The XBI is up 2.37%. MO...
Macro Rules: With Election Over Focus Reverts to Fiscal Cliff and Europe
Draghi Comments Trigger Sell-Off of 2% with Bottom Holding-Euro Down, Bonds Up Mario Draghi sparked the current 2012 rally in July saying he would support the Euro no matter what. Today reality set in as a weak German economy and riots in Greece remind us that little has changed. The Euro hit a...
Rayno Life Sciences-DX, Devices and Tools: CSII Revenues Up 25%
CSII ($12.17) stock is up 4.2% on sales growth in treatment of Peripheral Artery Disease (PAD) Cardiovascular Systems revenues were up 25% over Fiscal Q1 2012 to $23.3M . The Q1 2013 loss was $5,2M or 26 cents a share. Shareholder equity is $28.9M with $32M in cash and $11,8M in debt. CSII was...
Sell-Off Continues in Biotechnology Sector: Down 2% With High Fliers Down More
Huge Profits YTD Bring Selling-Momentum is Broken Profit taking has hit the biotechnology sector again today with major ETFs down 2% and momentum stocks hit harder. We recommended caution on 10/22 (see below) as momentum eased on stocks that were up over 100% YTD with the overall sector up 40%....